Open AccessCaplacizumab: First FDA-approved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura
Author(s) -
Feras Almarshad
Publication year - 2019
Publication title -
neuropharmac journal
Language(s) - English
Resource type - Journals
ISSN - 2456-3927
DOI - 10.37881/1.414
Subject(s) - medicine , thrombotic thrombocytopenic purpura , thrombocytopenic purpura , dermatology , platelet